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Background. After portal vein ligation of 1 side of the liver, the other side regenerates at a slow rate. This
slow growth may be accelerated to rapid growth by adding a transection between the 2 sides, i.e.,
performing portal vein ligation and parenchymal transection. We found that in patients undergoing
portal vein ligation and parenchymal transection, portal vein hyperflow in the regenerating liver causes
a significant reduction of arterial flow due to the hepatic arterial buffer response. We postulated that the
reduction of arterial flow induces hypoxia in the regenerating liver and used a rat model to assess
hypoxia and its impact on kinetic growth.
Methods. A rat model of rapid (portal vein ligation and parenchymal transection) and slow
regeneration (portal vein ligation) was established. Portal vein flow and pressure data were collected.
Liver regeneration was assessed in rats using computed tomography, proliferation with Ki-67, and
hypoxia with pimonidazole and HIF-1a staining.
Results. The rat model confirmed acceleration of regeneration in portal vein ligation and parenchymal
transection as well as the portal vein hyperflow seen in patients. Additionally, tissue hypoxia was
observed after portal vein ligation and parenchymal transection, while little hypoxia staining was
detected after portal vein ligation. To determine if hypoxia is a consequence or an inciting stimulus of
rapid liver regeneration, we used a prolyl-hydroxylase blocker to activate hypoxia signaling pathways in
the slow model. This clearly accelerated slow to rapid liver regeneration. Inversely, abrogation of hypoxia
led to a blunting of rapid growth to slow growth. The topical application of prolyl-hydroxylase inhibitors
on livers in rats induced spontaneous areas of regeneration.
Conclusion. This study shows that pharmacologically induced hypoxic signaling accelerates liver
regeneration similar to portal vein ligation and parenchymal transection. Hypoxia is likely an
accelerator of liver regeneration. Also, prolyl-hydroxylase inhibitors may be used to enhance liver
regeneration pharmaceutically. (Surgery 2016;j:j-j.)
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THE LIVER REGENERATES EXTENSIVELY AFTER INJURY TO
HEPATOCYTES, partial removal of liver tissue (partial
hepatectomy), and upon flow abrogation of 1 of
the 2 portal vein branches.1 Portal vein occlusion
may be achieved either through interventional
embolization or surgical ligation, while the hepat-
ic artery supplies oxygen and nutrition to the
ligated lobe. This maneuver, first described by
liver surgeons almost 30 years ago,2 results in
growth of the nonligated part of the liver. Liver
regeneration after portal vein manipulation
found its clinical application in liver operations
performed to increase the size of the disease-
free liver prior to extensive resections.3 With
this application, removal of previously unresect-
able liver tumors with extended hepatectomies
became possible.
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Portal vein occlusion results in only a moderate
amount of hypertrophy: 30–40% in 4–6 weeks.3 In
contrast, >50% hepatectomy is associated with a
rapid and extensive regeneration with the degree
of hypertrophy at 80–90% within 10 days.4 It is
interesting to note that, in contrast to partial hep-
atectomy, no tissue is removed during portal vein
occlusion. The observation that the liver regener-
ates after redirection of portal flow alone has led
to the hypothesis that changes in portal vein hemo-
dynamics may be contributing signals for liver
regeneration.5
This hypothesis has raised renewed interest after
a recent discovery: transection between the right
and left lobes in addition to portal vein ligation
(PVL + T) in humans, without any liver mass
removal, accelerates slow regeneration induced by
portal vein ligation (PVL) alone.6 This manipula-
tion induces extreme and rapid regeneration prior
to resection and allows for extended liver resections
after a week of waiting. The novel procedure in pa-
tients has been called “in-situ split hepatectomy”
or “ALPPS” (Associating Liver Partition and Portal
vein ligation for Staged hepatectomy), and it in-
duces the same kinetic growth rate as partial hepa-
tectomy (ie, rapid regeneration).7 The observation
has attracted considerable interest from liver sur-
geons because it allows in-situ liver regeneration of
an unknown extent.8 Also, adding simple tourni-
quet ligation of the parenchyma to contralateral
PVL has been found to achieve the same kinetic
growth rate as a more aggressive surgical procedure
with transection between the lobes.9
Due to the obliteration of collaterals and intra-
hepatic shunts by the added transection, a possible
trigger for rapid regeneration in the PVL + T
model may be the hyperflow in the portal vein (ie,
more volume flow per volume unit of liver tissue),
while experimental evidence is missing.10,11 In the
presence of portal hyperflow, there has been long-
standing evidence of a “buffer response” of the he-
patic artery.11 Upon increase of portal vein flow
per volume of tissue, the hepatic artery flow de-
creases accordingly to allow constant total sinusoi-
dal blood flow. Since the oxygenation of liver tissue
depends largely on the hepatic artery, we hypothe-
sized that PVL + T leads to hypoxia, which in turn
may be a stimulus of accelerated regeneration in
the growing liver. We used a rat model of PVL
and PVL + T to test this hypothesis.
METHODS
Human studies. Approval to perform the surgi-
cal procedure of PVL + T, the first stage of ALPPS,
in patients was obtained from the Ethics Committee
of the Kanton of Zurich in the context of a
prospective international registry (NCT01924741).
Consents for collection of intra- and perioperative
data were obtained from patients.
Portal vein ligation plus transection in human
patients. PVL + T was performed at 2 hospitals
(University Hospital Zurich and Kantonsspital Win-
terthur, Switzerland), as previously described.12
Hemodynamic measurements in human pa-
tients. Portal vein flow was measured using
16-mm flow probes (Transonic, Ithaca, NY), and
hepatic artery flow was measured using 4-mm flow
probes, expressed in mL/min. Portal vein pressure
was measured using Draeger Infinity Monitoring
system (Draeger, L€ubeck, Germany).
Animals. Approval for the experiments was
obtained from the Veterinary Authorities of the
Canton of Zurich, Switzerland (number 60/2014).
All experiments with male Wistar rats (Charles
River, Sulzfeld, Germany) were performed in
compliance with the guidelines for Experiments
on Animals by the Swiss Academy of Medical
Sciences and the Federation of European Labora-
tory Animal Science Associations guidelines. To
help condition them for the procedure, rats were
kept in ventilated cages (4 rats each) under stan-
dard pathogen-free conditions in a 12/12-hour
light/dark cycle for at least 5 days prior to the
performance of the procedure. The ambient
temperature was 22 ± 18C. Food and water were
provided ad libitum. The median weight of
the animals was 265 g (interquartile range [IQR]
250–295). We performed the volumetric studies by
computed tomographic (CT) imaging in 5 rats per
group. Likewise for tissue and blood samples,
groups of 5 animals were killed at each time point.
The exact number of animals per experiment (n)
is indicated in the figures.
Anesthesia animals. During all operative pro-
cedures, animals were allowed to breathe sponta-
neously under isoflurane anesthesia (Attane,
Piramal, Mumbai, India), 1.0–2.5 vol% vaporized
in 600 mL oxygen/min. Analgesia was provided
using a standard protocol of subcutaneous bupre-
norphine injections.
Model of slow and rapid liver regeneration after
PVL in rats. To develop models of slow and rapid
liver regeneration in rats, the right middle lobe
(RML 25% of total liver volume) Fig 1, A was cho-
sen as the liver remnant. Slow liver regeneration
(PVL, Fig 1, A) of the RML was induced by ligating
the portal vein of the right, the caudate, and the
left lateral lobe using 6-0 silk ties (Fig 1). Rapid
regeneration (PVL+T, Fig 1, A) was induced by
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additionally transecting along the ischemic line
with a nonsticking bipolar microforceps (Super-
gliss, Sutter GmbH, Freiburg i.B., Germany;
PVL + T). Sham operations with loose, nonocclud-
ing ligatures around the respective portal veins
(sham operated, Fig 1, C), and only transection be-
tween RML and left middle lobe (transection
alone, Fig 2, C) were used as controls.
Application of dimethyloxalylglycine. Twelve
hours before the operation dimethyloxalylglycine
([DMOG] Axxora Ltd, Nottingham, UK) was
intraperitoneally administered (200 mg/g body
weight).13 To examine the incidentally discovered
topical effect of DMOG on liver proliferation, we
used a small paint brush to apply the DMOG solu-
tion onto livers.
Application of myo-inositol-trispyrophosphate.
Myo-inositol-trispyrophosphate ([ITPP] Carbo-
synth, Compton, Berkshire, UK) was dissolved in
normal saline (200 mg/mL) and administered by
intraperitoneal injection of 0.3 mg/g of body
weight each, 12 hours before the operation.14 On
the first postoperative day, 0.1 mg/g of body
weight was again applied.
Hemodynamic measurements in rats. To assess
portal flow, 2-mm flow probes (Transonic, Ithaca,
NY) were used. Volume flow probes measure
volume directly rather than extrapolating from
flow velocity and vessel diameter. Portal vein
pressure was determined using pressure trans-
ducers and anesthesia monitors (Dr€ager, L€ubeck,
Germany).
Volumetry of rat livers. To assess regeneration
of the RML, animals underwent repetitive CT and
volumetry scanning every 24 hours for up to
72 hours (Quantum FX MicroCT, PerkinElmer,
Waltham, MA) after prior intravenous injection of
200 mL of the contrast ExiTron nano 12,000
(Miltenyi Biotech, Bergisch Gladbach, Germany).
Pimonidazole staining to quantify tissue oxygen-
ation. Pimonidazole was dissolved in normal saline
(100 mg/mL), and 60 mg were injected intrave-
nously 1 hour prior to harvesting the organs.15
Pimonidazole undergoes chemical reduction
under hypoxic conditions, binds irreversibly to
SH-containing molecules, such as glutathione
and proteins, and the resulting complexes accu-
mulate in hypoxic tissue. The pimonidazole bound
Fig 1. Anatomy and baseline volumetry of the rat liver and portal vein ligation models. (A) Anatomy of the 4 lobes of
the rat liver: right lobe (RL); middle lobe (ML) with right (RML) and left middle lobe (LML); left lateral lobe (LLL);
caudate lobe (CL). The ML is the only lobe supplied by 2 separate portal vein branches (*), taking off directly from the
main portal vein and is therefore the only lobe suitable for transection in the rat liver. (B) Absolute and relative volumes
of liver lobes as assessed in 16 Wistar rats undergoing computerized tomographic volumetry with intravenously applied
contrast. The largest lobe is the ML (36%), which may be divided into RML (26%) and LML (10%). (C) Models of
regeneration compared in this study. The surgical transection line divides the ML into the right middle lobe (RML)
and the left middle lobe (LML). In portal vein ligation (PVL), the portal veins supplying the right, left lateral, left
middle, and caudate lobe are ligated using silk ligatures. When the portal vein is ligated and the ML transected between
RML and LML, the model is called portal vein ligation and transection (PVL + T). In animals with transection alone, the
ML is transected, but the portal vein blood supply to both lobes remains normal. In sham-operated animals, non-
occluding ties are placed around the portal veins.
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in tissue was visualized with monoclonal antibodies
using immunofluorescence.
Histochemistry and immunofluorescence. Cryo-
sections of 6 mm were fixed using acetone (Sigma
Aldrich, St. Louis, MO) for pimonidazole staining
or paraformaldehyde 4% (Sigma Aldrich) for
10 minutes at room temperature for Ki-67 staining.
After 10 minutes, slides were kept in ice-cold
phosphate-buffered saline (PBS, Kantonsapotheke
Zurich, Switzerland) before the individual pro-
tocols were started. Slides were washed 3 times
for 5 minutes; then, they were blocked at room
temperature for at least 1 hour using 10% goat
serum (Sigma-Aldrich) with 1% bovine serum
albumin for pimonidazole staining or with
1 3 PBS+5% goat serum + 0.3% Triton X-100 for
Ki-67 staining. Incubation with the primary anti-
body took place at 48C overnight. The following
day a staining with an appropriate fluorochrome-
coupled secondary antibody took place for 2 hours
at room temperature; nuclei were stained using
4,6-diamidin-2-phenylindol (DAPI, Roche, Rotk-
reuz, Zug, Switzerland).
For staining of hypoxia-inducible factor-1a (HIF-
1a), formalin-fixed, paraffin-embedded liver tissue
was cut into 5 mm sections and placed on glass
slides. Sections were deparaffinized with xylene,
dehydrated with ethanol, and then incubated with
3% hydrogen peroxide to block endogenous perox-
idase. Antigen retrieval was performed by heating
in 10 mM sodium citrate buffer (pH 6.0). Sections
were blocked in DAKO protein block (X9090;
DAKO, Glostrup, Denmark), followed by incuba-
tion with primary antibodies, rabbit anti-HIF-1a
(Abcam 2185, diluted 1:800; Cambridge, UK); sec-
ondary antibodies were used to visualize target
proteins. DAB reagent (K3466; DAKO) was applied
in the detection procedure. Tissue sections were
counterstained with Aqua Hematoxylin-INNOVEX
(Innovex Biosciences, Richmond, CA). Negative
controls included liver specimens exposed to 1%
bovine serum albumin instead of to the respective
primary antibodies. The number of detected HIF-
1a immunoreactive cells was quantified by counting
in 20–40 randomly chosen, 203 fields per section
per animal.
The following primary antibodies were used:
rabbit anti-Ki-67 (Abcam, diluted 1:400) and rabbit
anti-pimonidazole (Hypoxyprobe, MA; diluted
1:200). Slides were mounted with ProLong Gold
Antifade Mountant (Life Technologies, Zug,
Switzerland).
Image acquisition and processing. Immunoflu-
orescence images were acquired with the Slides-
canner Axio Scan.Z1 (Zeiss, Feldbach, Zurich,
Switzerland) and the ZEN blue (Zeiss) image-
processing and analyzing software. A 203 objective
with aperture was used; the maximal intensity was
set to 5,247.
Determination of mean fluorescence intensity in
pimonidazole-stained liver slices. Image analysis
was performed using R: a language and environ-
ment for statistical computing16 and the EBImage,
an R package for imaging processing with applica-
tions to cellular phenotypes (R Foundation for
Statistical Computing, Vienna, Austria).17 Briefly,
variance in fluorescence intensity of liver slices
was expressed in relation to positive control (he-
patic artery ligation, mean variance = 100%) and
negative control (sham surgery, mean vari-
ance = 0%). The R code of this procedure is
included in the online only Data supplement.
Generation of a fusion image based on DAPI-
and Ki-67-stained liver slices and quantification of
Ki-67-positive cells. Red, green, blue (RGB) fusion
images from DAPI- and Ki-67–stained liver slices
were computed using R16 and the EBImage pack-
age.17 Matching DAPI- and Ki-67-stained fluores-
cence spots were also highlighted as red spots
using the “paintObjects” function. The R code of
this procedure is enclosed in the online only
Data supplement. The number of Ki-67 positive
cells was determined by evaluation of 5 random vi-
sual fields at 2003 magnification.
Experimental outcomes and statistical methods.
The primary outcome was liver hypertrophy
measured volumetrically in 24-hour intervals after
PVL and PVL + T. Secondary outcomes were
proliferation as assessed by KI-67 staining. Data
are means and standard deviations (SDs) for
normally distributed data, median, and IQR for
skewed data. For comparisons of normally distrib-
uted groups, we used the Student t test (2 groups)
or analysis of variance ([ANOVA] for >2 groups)
with Sidak-correction for multiple comparisons.
Details on the statistical analysis used for each
experiment are given in legends to Figs 2-6. Prism
6.0 (GraphPad Software Inc, San Diego, CA) was
used for data analysis and presentation.
RESULTS
Right middle lobe serves as the regenerating
lobe in the rat model. The rat liver consists of right,
middle, left lateral, and caudate lobes (Fig 1, A).
Small animal CT with intravenously applied
contrast injection allowed assessment of the vol-
umes of each lobe in an exact manner (Fig 1, B).
The only lobe in rodents that has inflow from 2
separate portal veins and may serve as a model
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for selective portal vein ligation, with or without
transection, is the middle lobe. We used the RML
as the regenerating lobe, because the portal vein
to the RML can be ligated easily, while ligation of
the portal vein to the LML requires resection of
the left lateral lobe and thereby a mass reduction
of the liver, which we tried to avoid. The RML
had a volume of 2.4 ± 0.5 mL or 26% of the total
liver in rats with a median weight of 265 g. In hu-
mans, a remnant volume of <30% generally re-
quires a procedure to increase the remnant
volume before resection.3 Figure 1, C shows the
types of portal vein occlusion procedures per-
formed to induce slow regeneration with PVL
and rapid regeneration with PVL + T.
Transection between lobes accelerates regener-
ation in the rat model. Representative CT scans
performed every 24 hours to assess the volume
increase of the RML are shown in Fig 2, A. Fine
lines drawn around the regenerating lobe to mea-
sure volume without sacrificing the animals are
highlighted (Fig 2, A). PVL and PVL + T resulted
in a significant volume increase within 24 hours af-
ter the operation of 44% and 74%, respectively,
while the sham-operated group showed no change
in liver volume (Fig 2, B). After 72 hours of contin-
uous growth, the relative volume increase of PVL
and PVL + T was 104% and 147% of the starting
volume, respectively; sham-operated animals did
not show significant changes in liver volume.
PVL + T led to a significantly higher volume in-
crease when compared with ligation alone.
The fraction of Ki-67 positive cells was evaluated
using immunofluorescence with evaluation of
Fig 2. Evaluation of growth kinetics in models of portal vein ligation using computerized tomographic (CT) volumetry
and immunofluorescence with Ki-67. (A) Small animal CT allows for an exact assessment of the volume of the
regenerating right middle lobe (RML): the orange line at 24, 48, and 72 hours after intravenous injection of a
nanoparticle-based contrast material. The regenerating RML appears less radio-opaque as it increases in size and is
clearly delineated. Representative scans for both portal vein ligation (PVL) and portal vein ligation and transection
(PVL + T) are shown. (B) Growth curves with means and standard deviations of liver volumes assessed by CT. Volume
of the RML increases significantly compared with sham-operated animals at 24 hours in animals undergoing PVL + T
(n = 5, #P = .01); at 48 hours in animals undergoing PVL (n = 5, &&P = .001) and PVL + T (##P < .001); at 72 hours in
animals undergoing PVL (&&&P = .006) and PVL + T (###P <.001). Transection alone does not lead to a significant
volume increase in the RML or other liver lobes (n = 5). Differences at 72 hours between PVL and PVL + T are
significant (:P = .001), ANOVA was used for comparison of groups. (C) Differential regeneration is histologically
evaluated using immunofluorescence with anti-Ki-67 antibody, marking mitotically active cells (red) in a background
of nuclear staining (DAPI, blue) at 3, 12, 24, and 72 hours after PVL and after PVL + T at 72 hours (white scale
bar = 1,000 mm). (D) Box plots with means and ranges of the proportion of Ki-67-positive nuclei per DAPI-stained
cell nuclei as counted in 20 high-power fields. PVL and PVL + Tare compared using ANOVA and multiple comparisons.
A significantly higher percentage of Ki-67 positive cells is observed in PVL + Tcompared with PVL at 3 hours (xP = .009),
24 hours (xxP < .001), and 72 hours (xxP < .001; n = 5 for each group), but not at 12 hours.
ARTICLE IN PRESS
Surgery
Volume j, Number j
Schadde et al 5
fluorescence signal in a slide scanner and digital
enlargement of positive signals at 3, 12, 24, and
72 hours (Fig 2, C). The proliferation rate of PVL
and PVL + T was significantly higher compared
with sham animals at 3, 24, and 72 hours, but
interestingly not at 12 hours (Fig 2, D). Prolifera-
tion was significantly increased in PVL + T at
3, 24, and 72 hours when compared with PVL.
There was no difference at 12 hours between
the 2 groups. The histologic proliferation data
confirmed the findings of volume increase by CT
in the rapid and the slow regeneration model
and shows that the degree of Ki-67 staining
correlates well with volumetrically measured liver
growth, except for the 12 hour time point.
Portal vein ligation induces portal hyperflow in
the regenerating liver in both the rapid and slow
regeneration models. Flow in the main portal
vein in 15 human patients before and after
PVL + T, the first step of the so-called “ALPPS”
operation in humans as reported elsewhere,6,12 was
704 ± 210 mL/min at baseline. Flow did not
change immediately after ligation and transection
or 7 days later (Fig 3, A1). Given that 70–80% of
the portal vein flow outflow is occluded in
PVL + T, no reduction in prehepatic hepato-petal
Fig 3. Flow and pressure studies of the human and rat main portal vein. (A) Volume flow in the main portal vein re-
mains unchanged despite a 75% portal vein ligation (PVL) and PVL with transection (PVL + T), resulting in portal hy-
perflow. (A1) In patients, main portal vein volume flow is 705 ± 219 mL/min and remains unchanged immediately after
right PVL + T and after re-exploration 7 days later (P = .292, n = 15). (A2) In rats, main portal volume flow does not
change from a baseline of 15 mL/min (IQR 12–16) after PVL (P = .198, n = 12). (A3) In rats, there is also no difference
in portal flow after PVL + T (P = .281, n = 17) for up to 24 hours. (B) Portal hyperflow results in increase in portal vein
pressure. (B1) In patients, main portal vein pressure increases from 12 ± 5 to 18 ± 4 mm Hg after PVL + T (*P = .002),
and the pressure stays elevated for up to 7 days at re-exploration (n = 15). (B2) In rats, portal vein pressure increases
from 4.3 (IQR 3.7–5.1) to 8.3 (IQR 7.0–8.6) mm Hg after PVL (**P = .004, n = 12). (B3) In rats, pressure increases
during the PVL step from 5.5 (IQR 4.7–6.0) to 8.7 (IQR 7.6–9.3) mm Hg (***P = .001, n = 17) and does not change
thereafter. (C) Flow in the hepatic artery of the liver remnant decreases during portal hyperflow in ALPPS. (C1) In pa-
tients, hepatic artery flow decreases in the left hepatic artery to the regenerating lobe from 116 ± 8 to 71 ± 70 mL/min
(##P = .014, n = 15), reflecting the buffer response of the hepatic artery to portal hyperflow. In contrast, it increases in
the right hepatic artery to the deportalized lobe from 227 ± 80 to 446 ± 190 mL/min (#P = .001, n = 15) to buffer the
lack of portal blood flow. Data are given as single data points, depending on normality, as mean ± standard deviation or
medians ± IQR. ANOVA (human data, n = 15) or Kruskal-Wallis test (rat data, n = 4) were performed for comparisons of
groups.
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volume flow in the main portal vein is indirect
proof of more flow per remnant liver volume
(20–30%) perfused (ie, “portal hyperflow”). Simi-
larly in rats, volume flow in the main portal vein
did not change from a baseline of 15 mL/min
(12–16 mL/min), neither after 75% portal vein
ligation and thereby flow space removal in PVL
(Fig 3, A2), nor after PVL + T (Fig 3, A3). Portal
vein pressures in humans undergoing PVL + T
increased significantly from 12 ± 5 mm Hg prior
to the procedure to 18 ± 4 mm Hg after ligation
and transection and stayed elevated for 7 days
(Fig 3, B1). Similarly in rats, portal vein pressures
in the main portal vein undergoing PVL (Fig 3,
B2) and PVL + T (Fig 3, B3) increased significantly
after the portal vein ligation step. However, the
added transection in PVL + T did not increase
the pressure further (Fig 3, B3). Pressure remained
elevated at 3, 12, and 24 hours in both the PVL and
PVL + T groups.
Reduced arterial flow in PVL + T in patients.We
measured arterial flow in the human liver remnant
before and after the first stage of the “ALPPS”
operation in humans. Flow in the left hepatic artery
decreased significantly from 116 ± 80 mL/min
at baseline to 71 ± 70 mL/min after PVL + T,
likely an adaptation to the portal hyperflow, known
as the hepatic arterial buffer response10,18 (Fig 3,
C1). This decrease in arterial flow remained un-
changed for up to 7 days. The flow in right hepatic
artery to the deportalized lobe after PVL + T
increased from a baseline of 227 ± 80 mL/min to
446 ± 190 mL/min (Fig 3, C1). This upregulation
in flow also may be explained by the hepatic arterial
buffer response and remains unchanged for up to
7 days after the operation.
Pimonidazole staining demonstrates local tissue
hypoxia in rapid regeneration. To identify hypoxic
areas in the regenerating liver, pimonidazole was
used as a well-known marker for detection of
hypoxic tissues.19 Immunohistochemistry showed
no specific signal in sham-operated animals
(Fig 4, A). Upon hepatic artery ligation in rats
(positive control), staining in the zone around
the central vein was found (Fig 4, B). No specific
signal was identified in regenerating hepatic tissue
after PVL (Fig 4, C). However, there was intense
staining after PVL + T (Fig 4, D). We used
immunofluorescence-stained slides for quantifica-
tion (Fig 4, E) based on an algorithm to assess
the contrast between specific and nonspecific
staining (online only Data supplement). In this al-
gorithm, the variance in pixel intensity of liver tis-
sue was assessed. Relative values were calculated by
setting the mean variance of liver slices after sham
surgery at 0%, while the mean variance of all liver
slices after hepatic artery ligation was set at 100%
(Fig 4, E). While there was no difference between
PVL and sham-operated animals, PVL + T showed
significant hypoxia, comparable to hepatic artery
ligation, in the regenerating liver lobe at 3 and
12 hours (Fig 4, F). HIF-1a expression quantified
by immunohistochemistry was higher in PVL + T
when compared with PVL alone (Fig 4, G).
Rapid regeneration can be induced in the slow
regeneration model by activation of hypoxic
signaling pathways. Prolyl hydroxylase domain
(PHD) 1–3 oxygen-sensing enzymes are natural
gatekeepers of the adaptive response to hypoxia.20
Under normoxia, PHD are constantly marking the
continuously transcribed and translated HIF-1a
subunits for degradation, while in hypoxia, the
substrate for hydroxylation is missing. As a conse-
quence, HIF-1a is upregulated and activates
numerous hypoxic signaling pathways. With the
hypothesis of pharmacologically changing slow to
rapid liver regeneration, the PHD inhibitor
DMOG was given to animals prior to PVL (slow
regeneration). This intervention led to an enlarge-
ment of the RML volume from a baseline of
2.5 ± 0.5 mL to a final volume 6.6 ± 0.4 mL at
72 hours with increases of 60 ± 14% at 24 hours,
88 ± 11% at 48 hours, and 134 ± 21% at 72 hours
(Fig 5, A). This degree of volume increase was
not different at any time point from PVL + T,
and was significantly higher than the volume in-
creases observed after PVL. Intraperitoneal injec-
tion of DMOG in rats undergoing sham surgery
as a control led to no change in starting volume.
DMOG in PVL also led to an increase in the pro-
portion of Ki-67 positive cells (Fig 5, B). The
mitotic activity after PVL + DMOG was even higher
than after PVL + T (P = .023; Fig 5, C). There was
no significant difference in the proportion of Ki-67
positive cells between sham-operated animals and
sham-operated animals receiving DMOG prior to
the operation. While DMOG given systemically
before sham operation seemed to have no signifi-
cant overall proliferative impact on liver tissue,
when DMOG was applied locally to the surface of
liver tissue, geographic areas of hypertrophy were
visible on the liver surface (Fig 5, D). Ki-67 staining
showed 1-mm-deep areas of high proliferation
(Fig 5, E) compared with areas from control ani-
mals that appeared macroscopically normal
(P < .001; Fig 5, F).
Reversing hypoxia by increasing oxygen delivery
to the regenerating liver blunts rapid liver regen-
eration. ITPP is an allosteric effector of hemoglo-
bin and enhances the capacity of hemoglobin to
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release oxygen in tissue.21 It is well known that this
compound substantially abrogates hypoxia in tu-
mors, leading to reduced tumor growth.22,23 We
therefore tested to see if rapid regeneration could
be abrogated by increasing oxygen delivery to the
growing liver by treating the group of animals un-
dergoing PVL + T. When given 12 hours before
and at the first day after the operation, ITPP clearly
reduced liver regeneration after PVL + T. Right me-
dian lobe volume changed from a baseline volume
of 2.3 ± 0.2 mL to only 4.8 ± 0.6 mL at 72 hours
(P < .001), a reduced volume increase over time
(Fig 6, A). This volumetric growth was not different
at any time point from growth after PVL, but signif-
icantly decreased compared with the volume in-
crease observed after PVL + T. Intraperitoneal
injection of ITPP in rats undergoing sham surgery
led to no change in volumetry volume.
Application of ITPP prior to PVL + T led to less
Ki-67 positive cells compared with PVL + T at
72 hours (Fig 6, B). The degree of mitotic activity
in PVL + T plus ITPP was decreased significantly
and not different from PVL (Fig 6, C). There
was no significant difference in the proportion of
Fig 4. Hypoxia staining using pimonidazole in the regenerating liver lobe. (A) Pimonidazole immunohistochemistry
shows no signal after sham surgery (negative control; *central veins, #portal tracts, scale bar: 100 mm). (B) After complete
hepatic artery ligation, there is a strong signal around the central veins (arrows), a positive control for hypoxia (*central
veins, #portal tracts, scale bars: 100 mm). (C) There is no specific pimonidazole staining of the liver tissue after portal vein
ligation alone (PVL), while (D) PVL and transection (PVL + T) lead to distinct zone 2 hypoxia (arrows; *central veins,
#portal tract). (E) The results obtained by immunohistochemistry were confirmed by immunofluorescence and quanti-
fied. Entire tissue blocks were exposed in an immunofluorescence slide scanner overnight to compare the variance of
fluorescence intensity of regenerating liver tissue after PVL + T at 3, 12, and 24 hours and regenerating liver tissue after
PVL and compared with sham surgery (3 h) and hepatic artery ligation (3 h; scale bars: 1,000 mm). (F) Hypoxia
by pimonidazole morphometry. Variance of pimonidazol-positive versus pimonidazol-negative areas. Two-way
ANOVA and multiple comparisons between groups (n = 4 animals per group with 4 sections per animal) were performed
(*3 hours PVL 24 ± 51 vs PVL + T 104 ± 83, P = .001; **12 hours PVL 21 ± 59 vs PVL + T 85 ± 85, P = .01). At 24 hours,
there was no significant difference. (G) Hypoxia by hypoxia-inducible factor-1a (HIF-1a) morphometry. HIF-1a positive
cells were counted in 10 or 20 high-power fields in 4 animals per group and expressed in relation to sham-operated
animals as x-fold change in signal. ANOVA and multiple comparisons were used to determine significance. There was
a significant increase in HIF-1a signal in PVL + T at 3, 12, and 24 hours compared with PVL (3P < .001 for 3, 12, and
24 hours).
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Ki-67 positive cells between sham-operated animals
with or without ITTP treatment.
DISCUSSION
This study provides first evidence that hypoxia
modulates the kinetic rate of liver regeneration. Our
finding of hypoxia in liver remnants undergoing
rapid liver regeneration was supported by the trans-
formation of slow regeneration into rapid regener-
ation using a PHD inhibitor. In contrast, increase in
oxygen delivery to the rapidly regenerating lobe
using ITPP abrogated rapid regeneration and
reduced it to the slow liver regeneration found after
PVL. Importantly, the PHD inhibitor DMOG addi-
tionally triggered de-novo regeneration of 1 mm
depth upon local application to rat livers without
any portal vein manipulation. This group of drugs is
currently in clinical phase III trials for applications
unrelated to liver regeneration and will have to be
evaluated as a therapeutic agent for drug-inducible
liver regeneration. (see schematic Fig 7)
Based on our findings, hypoxia may be the rate
determining mechanism for rapid regeneration
after PVL + T. While there is no hypoxia present in
the slowly regenerating liver after PVL, the regen-
erating lobe after PVL + T seems profoundly
hypoxic as shown by pimonidazole staining. This
degree of hypoxia may be explained by the
reduction of oxygen-rich arterial flow in the
regenerating liver lobe in PVL + T as assessed in
our arterial flow studies in humans. In contrast,
this mechanism may have little or no importance
Fig 5. Pharmacologic activation of hypoxic-signaling pathways using prolyl-hydroxylase inhibitors. (A) Systemic applica-
tion of dimethyloxaloglycine (DMOG) accelerates slow liver regeneration after portal vein ligation (PVL) to rapid liver
regeneration for 72 hours. The differences in volume between PVL and PVL + DMOG are significant at *24 hours
(P = .028), **48 hours (P = .006), and ***72 hours (n = 8; P = .006); data are mean ± standard deviations. ANOVA
and multiple comparisons were used for comparison between groups. (B) Ki-67 staining of the right median lobe
(RML) after 72 hours shows that DMOG added to PVL induces very high proliferative rates comparable in mitotic ac-
tivity to portal vein ligation and transection (PVL + T). DMOG added to sham surgery alone does not increase prolif-
eration. (C) Box plots (minimal to maximal value) show Ki-67 positive nuclei in percentage of DAPI-stained nuclei.
Quantification was performed by evaluation of 20 high-power fields (HPFs) per animal. PVL + DMOG has 44 ± 10%
signal compared with 19 ± 13% in the PVL group (#P < .001) and 35 ± 9% PVL + T (##P = .023). DMOG in animals
undergoing sham surgery (8 ± 6%) results in no significant increase compared with sham surgery alone (4 ± 3%).
ANOVA and multiple comparisons were used for comparison between groups. (D) Photograph of the geographic areas
of liver regeneration visible on the surface of the entire liver after local application of DMOG onto the liver. (E) Repre-
sentative Ki-67 staining of a mitotically active zone of 1-mm depth from the surface in areas of regeneration shows
40 ± 9% Ki-67 positive cells compared with (F) 3 ± 5% Ki-67 positive cells in areas of control liver tissue (scale bars
in all photographs are 1,000 mm).
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when there is compensatory blood flow between
liver lobes through sinusoidal collaterals such as in
PVL. Interestingly, reduced arterial flow has been
demonstrated repeatedly in regenerating livers in
animal models of partial hepatectomy,24-26 small-
for-size live donor liver transplantation25,27 and in
models of liver regeneration after PVL,10 but its
role as the accelerator of liver regeneration has
so far not been understood.
In the rat model of PVL, we were not able to
measure arterial flow to the regenerating lobe
directly due to technical limitations, namely the
unavailability of very small-volume flow probes.
However, the precise physiological measurements
by Rocheleau et al,10 using radiolabeled micro-
spheres, demonstrated that in the rat liver with
portal hyperflow arterial flow is reduced from
1 mL/min to 0.5 mL/min. Interestingly, we also
observed about 50% reduction in arterial flow in
our human flow measurements. In the study by
Rocheleau et al,10 the liver with arterial flow grew
in size. The authors also demonstrated a correla-
tion between decreasing arterial flow in the regen-
erating lobe and increasing portal flow. Essential to
keeping portal flow constant, hepatic arterial au-
toregulation was first described as the “hepatic
Fig 6. Pharmacologic deactivation of hypoxic signaling by increasing tissue oxygen delivery using myo-inositol-
trispyrophosphate (ITPP). Systemic application of ITPP via an intraperitoneal injection decelerates rapid liver regenera-
tion of portal vein ligation and transection (PVL + T) to slow liver regeneration. (A) Application of ITPP to rats
undergoing PVL + T blunts rapid hypertrophy significantly to only a modest increase of 24 ± 6% at 24 hours
(PVL + T: 74 ± 38%), 63 ± 18% at 48 hours (PVL + T: 111 ± 30%), and 107 ± 21% at 72 hours (PVL + T:
147 ± 16%). Volume increase after addition of ITPP is significantly lower compared with PVL + T at *24 hours
(P = .011), **48 hours (P = .006), and ***72 hours (n = 6; P = .003). ANOVA and multiple comparisons were used for
comparison between groups. (B) Ki-67 staining of the right median lobe (RML) 72 hours after PVL + T plus ITTP shows
reduced mitotic activity after ITPP application, similar to PVL. Sham surgery and ITPP application alone serve as a nega-
tive control. (C) Box plots (minimal to maximal value) show Ki-67 positive nuclei in % of DAPI-stained nuclei. Quanti-
fication is performed by evaluation of 20 high-power fields per animal. PVL + T with additional ITPP had 18 ± 8% signal
compared with 35 ± 9% in the PVL + T (#P< .001) and 19 ± 13% in PVL. PVL + T + ITPP show no difference compared to
PVL (P = .999). ITPP in animals undergoing sham surgery results in no change compared with sham surgery alone. AN-
OVA and multiple comparisons were used for comparison between groups.
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arterial buffer response”11 and was explained by
the differential washout of adenosine with
different degrees of portal flow.18 Interestingly,
based on this physiological effect, hypoxia has
been postulated repeatedly to “accompany” liver
regeneration.5,10 In stark contrast to our findings,
hypoxia has been viewed by most as detrimental
to liver regeneration,28 and abrogating hypoxia
through surgical maneuvers, like portal vein arteri-
alization, has been considered beneficial to the re-
generating liver.25
Recently, investigators described the presence of
the master regulator of hypoxia HIF-1a in regen-
erating livers after resection,29,30 not just in
response to hypoxic injury but as an important
regulator of hepatic metabolism in general.31,32 It
also has been demonstrated that liver regeneration
is actually increased in mice deficient for PHD-1
and that increased HIF-1a activity in the regenerat-
ing liver not only induced a protective response,
but also accelerated liver regeneration.33 We actu-
ally speculated that hypoxia sensing might be
used therapeutically in extended liver resections
and liver transplantation, and our study supports
these ideas. Our finding of differential degrees of
liver regeneration after portal vein manipulation
and the pro-mitotic effect of the local application
of a PHD inhibitor allowed us to show that hypoxia
sensing not only enhances liver regeneration, but
also may serve as an initiator of liver regeneration
independently of portal hyperflow.
Very recently, the powerful effect of stabilization
of HIF-1a, and thereby hypoxia sensing on regen-
erative processes, has been pointed out in a model
of epidermal wound healing.34 It was shown that
the PHD inhibitor 1,4-dihydrophenonthrolin-4-
one-3-carboxylic acid used in a local gel application
in B6 mice in the ear punch hole model leads to
accelerated wound healing via the dedifferentiation
and mobilization of progenitor cells. We speculate
that similar processes of cell reprogramming to
glycolytic progenitor cells in the liver and further
generation of hepatocytes from progenitor cells
may be initiated and controlled by arterial flow
Fig 7. Schematic of the proposed mechanism of rapid hypertrophy induced by hypoxia of the liver remnant. Under
normoxic conditions, like portal vein ligation (PVL), prolyl-hydroxylases 1-3 (PHD 1-3) hydroxylate prolyl residues
on the HIF-1a, which leads to the binding of Von-Hippel-Landau protein (pVHL), ubiquinisation (Ub), and degrada-
tion of HIF-1a. Arterial hypoxia in portal vein ligation and transection (PVL + T) leads to a blockade of PHD 1-3, al-
lowing binding of HIF-1a to the coactivators EA1 binding protein p300/CREB binding protein (P300/CBP) and
transcriptional activation of over 200 HIF-1a target genes, some of which may have a role in accelerating liver regener-
ation. Dimethyloxalylglycine (DMOG) blocks PHD 1-3 and thereby allows HIF-1a stabilization in cells, induction of hyp-
oxia signaling, and acceleration of liver regeneration. Myo-inositol tri-pyrophosphate (ITTP) increases oxygen delivery
by allosteric conformational change of the hemoglobin molecule and thereby restores normoxia, blunting rapid liver
regeneration.
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restriction in the regenerating liver, inducing
hypoxia-signaling pathways. Which cells constitute
these progenitor cells remains unclear. Using Ki-
67 staining, we observed 2 peaks of proliferation:
1 immediately after the procedure at 3 hours, fol-
lowed by a decrease in proliferative activity at
12 hours and then an increase at 24 hours. It is
well known that 2 stages of liver regeneration
occur.35-37 The first consists of the activation of
signaling pathways, including growth factors, cyto-
kines, neuroendocrine factors, and paracrine sig-
nals (called priming phase), peaking between
2–3 hours after the operation. It is followed by a sec-
ond proliferative phase with hepatocyte DNA syn-
thesis,37 with maximum activity between 24 and
48 hours. While in our study regeneration activity
in the liver with PVL seems to be absent in the
priming phase at 3 hours, there is proliferation in
the PVL + T at this very early stage. PVL + T may
accentuate the priming phase of regeneration.
Additional study will help us learn why this early
proliferation occurs. Hypoxia in PVL + T may
induce early cell proliferation. Through transec-
tion, collateral flow between RML and LML is inter-
rupted completely, which further increases the
concentration of growth and inflammatory media-
tors in the RML, possibly accentuating and acceler-
ating regeneration processes.
Several groups have presented animal models
of the PVL + T procedure.38,39 One study in rats
demonstrated accelerated hypertrophy of the
RML after PVL + T, the same model we used.
The authors hypothesized that interruption of
vascular shunts between the deportalized and
the regenerating liver may explain rapid hypertro-
phy in PVL + T,38 but they did not assess the he-
modynamic effects of the operation. They
speculated that the increased growth rate of
PCL + T may be explained by hepatocellular dam-
age and necrotic areas in the deportalized LML
via an increased expression pattern of inflamma-
tory mediators, like IL-6 and TNF-a. Another
study examined PVL + T, but the authors did
not really use a model of rapid hypertrophy
without mass reduction. They combined liver
resection of the left lateral lobe with PVL + T,
and thereby created a partial liver resection and
portal vein occlusion model at the same time.
Their study suggested that rapid hypertrophy
was purely a result of systemic trauma induced
by the transection of the liver and also could be
induced by operative damage to the spleen and
lungs.39 However, in our study, PVL combined
with tourniquet instead of transection also
induced an acceleration of volumetric growth
similar to reports in patients undergoing PVL
with tourniquet ligation instead of transection.9
Therefore, our study supports the concept that
abrogation of collateral flow, rather than the
trauma caused by transection alone, plays the
key role in modulating regenerative kinetics.
Flow and pressure measurements in patients
undergoing PVL + T as a liver resection strategy
revealed that flow volume in the main portal vein
did not change after PVL + T. However, an
increase in portal vein pressure was observed.
These findings were confirmed in our rat model.
Given these findings, we conclude that portal
hyperflow, arithmetically 4 times the flow per
tissue unit, results in increased portal vein pres-
sures in PVL as well as PVL + T. We further
investigated the hepatic arterial buffer response in
the regenerating liver. Flow measurement in
humans showed that the hepatic arterial flow to
the regenerating liver was decreased significantly
in PVL + T. The observation that transaminases
are significantly higher after PVL + T than they are
after PVL alone, in our experience and in both
experimental articles on PVL + T,38,39 may be ex-
plained by hypoxic cell death rather than by the
trauma of transection.
Because we were unable to measure rat arterial
volume flow, we chose to induce hypoxia sensing
by activating HIF-1a pathway in the regenerating
lobe after PVL using the well-established PHD
inhibitor DMOG. We hypothesized that this might
increase the regenerative rate in the same way that
adding a transection between the lobes would.
DMOG given to rats undergoing PVL induced a
similar acceleration of regeneration as performing
a transection between the regenerating and the
deportalized lobe. Interestingly, we observed that
the local application of DMOG to rat livers also
induced a 1-mm deep area of liver regeneration of
hepatic tissue without any portal vein manipula-
tion. While augmentation of liver regeneration has
been reported after partial hepatectomy in PHD-1
knockout mice,33 a triggering role for regenera-
tion without liver resection has so far not been
described.
DMOG, however, may influence other pathways
beyond HIF-1a subunit stabilization. To demon-
strate that hypoxia sensing is the catalyst of rapid
hypertrophy, we needed to confirm that increase
of tissue oxygen abrogates rapid hypertrophy and
switches the rapid to the slow regeneration. We
therefore used ITPP as an allosteric hemoglobin
regulator to increase oxygen delivery to liver tissue.
Rapid hypertrophy with the high mitotic rate was
blunted substantially.
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In conclusion, this study includes patient and
animal data to provide the first evidence that
hemodynamic changes and resulting hypoxia may
explain rapid liver regeneration. It also points out
the possible potential of PHD inhibitors to accel-
erate the slow regeneration associated with portal
vein occlusion. Pharmacologic simulation of hypoxia
may offer clinical advantages and may replace the
surgical practice of PVL + T in the form of “ALPPS,”
an operation that, while opening new surgical
options, has been proven to be fraught with com-
plications and a prohibitively high mortality rate.40,41
We acknowledge the contribution of Tobias Piegeler,
MD to the collection of data for the animal experiment
and to the drafting of the first version of this paper.
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online at http://dx.doi.org/10.1016/j.surg.2016.05.018.
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Installation of Bioconductor and EBImage library 
To run the following code, please install the latest release of R (https://www.r-project.org/), 
then get the latest version of Bioconductor by starting R and entering the commands: 
source("http://bioconductor.org/biocLite.R") 
biocLite("EBImage") 
 
# Load EbImage library 
library("EBImage") 
 
Generation of a fusion image based on DAPI- and Ki-67-stained liver slices 
This function highlights matching Ki-67 and DAPI fluorescence spots after fusion of images 
“ki67_img” and “dapi_img”. A highlighted RGB Image is written to disk to allow a later 
visual verification of the automated quantification procedure. 
Computeki67Image <- function(ki67_img, dapi_img) 
{ 
    # Read images 
    ximg1 <- readImage(ki67_img) 
    ximg2 <- readImage(dapi_img) 
 
    # Convert to gray scale        
    b <- channel(ximg2, "gray") # DAPI 
    r <- channel(ximg1, "gray") # ki67 
       
    # Track down spots in k67 stainings 
    # by thresholding intensities between 80-100% 
    ximg1_flat <- ximg1 > 0.8 
    ximg1_flat[ximg1_flat >  0.8] <- 1 
       
    # Apply bitwise AND to merge DAPI and ki67 stainings 
    z_img <- b & channel(ximg1_flat, "gray") 
       
    # Dilate matched spots 
    kern = makeBrush(7, shape='disc') 
    z_img2 = dilate(z_img, kern) 
       
    # Estimate area of the liver slice in both stainings 
    # First, the DAPI staining 
    negmask1 <- b 
    negmask1[negmask1 > 0.1] <- 1 
    negmask1[negmask1 < 1] <- 0 
 
    # Second, the ki67 staining       
    negmask2 <- r 
    negmask2[negmask2 > 0.1] <- 1 
    negmask2[negmask2 < 1] <- 0 
       
    # Combine the mask using bitwise AND  
    negmask <- negmask1 | negmask2 
 
    # Filter out black holes in the slice area       
    negmask = gblur(negmask, sigma=6)  
    negmask[negmask > 0.01] <- 1 
    negmask[negmask < 1] <- 0 
       
    # Do segmentation procedure 
    c <- bwlabel(negmask) 
  
    # Compose a merged rgbImage 
    fximg <- rgbImage(green=channel(ximg1, "gray"),  
  blue=channel(ximg2, "gray"),  
  red=z_img2) 
       
   # Compose a merged rgbImage and write it to disk    
    res = paintObjects(c, fximg, col='#ff0000', thick=TRUE) 
    writeImage(res, paste(ki67_img, "_marked.png"), 'png') 
 
    # Return the data in data.frame 
    return filename=ki67_img   
} 
 
Determination of mean fluorescence intensity in pimonidazole-stained liver slices 
This function calculates the mean pixel intensity of the largest, contiguous area of a tissue 
slice contained “fname”. A highlighted RGB Image is written to disk to allow a later visual 
verification of the automated quantification procedure. 
ComputePimonidazoleImage <- function(fname) 
  { 
    # Read image file 
    ximg = readImage(fname) 
 
    # Threshold pixel intensities above 10%     
    ximg2 <- ximg > 0.1 
 
    # Deal with black spots in the respective area 
    g_t = fillHull(ximg2) 
     
    # Basic morphological operations facilitating the segmentation 
    kern = makeBrush(10, shape='disc') 
    g_t2 = dilate(erode(g_t, kern), kern) 
    kern3 = makeBrush(50, shape='disc') 
    g_t3 = erode(g_t2, kern3) 
 
    # Do the segmentation procedure    
    cmask = bwlabel(g_t3) 
    b = channel(cmask,"r") 
     
    # Write an RGB image for visual verification 
    res = paintObjects(b, ximg, col='#ff0000', thick=TRUE) 
    writeImage(res, paste(fname, '_marked.tiff'), 'tiff') 
 
    # Compute mean pixel intensity of the largest, contiguous area 
    ft = computeFeatures(b, res) 
    xy <- which.max(ft[, "x.0.s.area"]) 
    imean <- ft[ xy , "x.a.b.mean"] 
    isd <- ft[ xy , "x.a.b.sd"] 
# Return the data in a data.frame 
    z <- data.frame(fname=fname, m=imean, s=isd) 
    return(z) 
} 
